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Molecular typing techniques such as restriction fragment length
polymorphism (RFLP), pulsed-field gel electrophoresis
(PFGE), arbitrary primed polymerase chain reaction (AP-PCR)
and ribotyping have been used to distinguish between Hel-
icobacter pylori isolates for epidemiologic analysis [1]. All methods
have, to a lesser or greater extent, been able to distinguish
between different isolates. RFLP performed on PCR ampli-
fication products of the H. pylori flagellin gene flaA has pre-
viously been suggested as a tool for differentiation of H. pylori
strains, due to the extensive diversity of the flaA gene [2]. AP-
PCR is a method used to create genomic fingerprints mainly
from species where very little is known about the target
sequence. Arbitrary oligonucleotides are used to prime DNA
synthesis from genomic sites which they fortuitously match or
almost match. AP-PCR is more simple and less expensive than
RFLP.
Studies using different molecular typing techniques have
shown contradictory results concerning the number of H. pylori
strains in the stomachs of individual patients. Infections both
with multiple strains [3,4] and with single strains [5,6] have
been reported. It has been suggested that the expression of
virulence genes such as cagA and vacA is associated with disease.
The gene cagA is a marker for a genomic pathogenicity island
of about 40 kbp, which contains genes encoding proteins that
are thought to enhance the virulence of the strain [7–9]. H.
pylori produces a toxin, VacA, which causes vacuolation in
epithelial cells.
The primary aim of the present study was to fingerprint H.
pylori isolates from patients in whom H. pylori infection had
recurred after antimicrobial treatment, in order to determine
whether the patients were reinfected with a new strain or were
still infected with the original strain (recrudescence), and to
compare the application of two methods, AP-PCR and RFLP
of the flaA gene. The secondary aim was to see whether dif-
ferences in the presence of virulence factors (cagA and vacA) in
H. pylori strains were related to treatment outcome.
Thirty patients were included in a study approved by the
ethics committee at Huddinge University Hospital and per-
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formed at the Center of Gastroenterology, Huddinge Uni-
versity Hospital. Patients with dyspepsia were referred to the
clinic for upper endoscopy, and were included if a rapid urease
test (CLO test, Delta West, Bentley, Australia) was positive.
After informed consent, the patients were randomized into two
treatment groups: (1) 16 patients received omeprazole (Losec,
Astra, Ha¨ssle, Sweden) 20 mg twice-daily, amoxycillin (Amox-
icillin NM Pharma, NM Pharma, Stockholm, Sweden)
1000 mg twice-daily, and metronidazole (Flagyl, Rhoˆne-Poul-
enc Rorer, Paris, France) 400 mg twice-daily (OAM); and (2)
14 patients received omeprazole (Losec) 20 mg twice-daily,
clarithromycin (Klacid, Abbott Laboratories, Chicago, IL,
USA), 250 mg twice-daily, and metronidazole (Flagyl) 400 mg
twice-daily (OCM). The patients were treated for 7 days.
Biopsies were taken from antrum and corpus of the stomach
before (day 0), during (day 7) and after (day 35) treatment.
Samples were used for CLO tests, histology and cultivation.
These patients also had a [13C]urea breath test at days 0, 7 and
35.
The success rate was 100% in the OCM group and 71% in
the OAM group, i.e. four patients were colonized with H.
pylori after treatment as demonstrated by positive cultures, CLO
test, [13C]urea breath test (UBT) and histopathology [10]. H.
pylori was not isolated at day 7 in any of the patients.
The isolates from these four patients (A–D) were further
analyzed. The biopsies were weighed, homogenized, diluted
and cultured on selective media incubated in a micro-aerobic
ddenvironment (CampyPak, BBL, Cockeysville, USA) at 37 °C
for 5 days. The susceptibility of the isolates before and after
treatment to amoxycillin, clarithromycin and metronidazole
was tested by Etest (Biodisk, Solna, Sweden). Approximately
50 colonies from antrum and 50 from corpus, both before and
after treatment, were picked randomly from primary cultures
of the four patients (A–D). Each isolate was recultivated and
lysed with a Sputum Sample Preparation Kit (Roche, Basel,
Switzerland). The DNA was frozen until assayed. The strains
were examined by AP-PCR in duplicate, with only one 19-bp
primer [10]. Representative isolates from each patient with
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minor differences in AP-PCR patterns were used for RFLP
after amplification of the H. pylori flagella gene flaA [2,5].
Restriction enzymes HhaI, DnpII and AluI were used separately.
All colonies (n = 794) were tested for the presence of the cagA
gene. A PCR assay for the specific detection of the 400-bp
fragment of the cagA gene of H. pylori was performed according
to Tummuru et al [11]. Three to 10 isolates from each patient
and location were used for vacA identification. They were
characterized by differences in the signal sequence (s1/s2) and
middle region (m1/m2) of the gene according to the study
performed by Atherton et al [12].
In patient A, H. pylori was isolated only from the antrum,
while in patients B–D, H. pylori was isolated both from the
antrum and the corpus of the stomach. Minimal inhibitory
concentrations (MICs) could not be evaluated for patients A
and D, due to poor viability of the strains. All isolates tested
were susceptible to amoxycillin and clarithromycin
(MIC  0.016 mg/L). Patients B and C harbored metron-
idazole-resistant strains (MIC  32 mg/L), whereas only 20%
of the successfully treated patients had metronidazole-resistant
strains.
With AP-PCR, very minor differences in band patterns, 0–
3 bands, were identified within isolates from each patient, but
large differences of 4 bands were noted between patients.
Isolates representing minor-difference patterns with AP-PCR
from each individual patient were subjected to RFLP. All col-
onies from the same patient gave an identical RFLP pattern in
each of the three digestions, as exemplified by patients B and
C in Figure 1. In each patient, isolates from antrum and corpus
showed the same pattern. Clear differences, 3 bands, were
seen between the patients (Figure 1).
Figure 1 RFLP patterns of the flaA gene of H. pylori isolates with minor differences in AP-PCR (not shown) from two patients: lanes 1 and 2,
patient B; lanes 3–7, patient C. The flaA gene was cut with enzymes AluI, DnpII and HhaI.
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In patient A, all colonies were cagA negative before and after
treatment. In patients B and C, all colonies were cagA positive
before and after treatment, in antrum as well as in corpus. In
patient D, both cagA-positive and cagA-negative colonies were
present. Eighty-six per cent (55/64) were cagA positive in
antrum before treatment, and 84% (54/64) in corpus. After
treatment, 91% (43/47) were cagA positive in antrum, and 96%
(44/46) in corpus. The signal region s1 was present in most of
the tested strains, and the s2 allele was present in only two
strains from patient B. The most common middle region was
m2, although all isolates from patient B harbored the m1 allele.
We analyzed about 100 pre- and post-treatment isolates
from each patient. The minor AP-PCR differences seen within
patients might be due to plasmid content and genomic diversity,
and we did not regard them as defining different strains or
genotypes. Taylor et al have shown that the H. pylori genotype
can remain stable in vivo for years, despite the acquisition or
loss of drug resistance [13]. When our isolates were finger-
printed with RFLP of the flaA gene, an identical pattern was
seen in all isolates from a single patient. We believe that this
indicated that the patients were colonized with only one strain
of H. pylori. Forbes et al typed 49 isolates of H. pylori originating
from independent sources with no known epidemiologic links,
using RFLP of the PCR product of the flaA gene: the isolates
were easily discriminated into 37 groups. These authors suggest
that the degree of discrimination obtained by this method
would permit the identification of individual strains in clinical
situations such as the differentiation of recrudescence from
reinfection [2]. In our study, the H. pylori isolates 4 weeks after
the end of treatment were all identical to the pretreatment
isolates in each of the four patients, according to both typing
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methods, AP-PCR (permitting 3 band differences) and
RFLP, indicating recrudescence. Other studies on patients from
developed countries, where less isolates were fingerprinted, also
found single-strain infections of H. pylori [5,6]. Multiple strains
of H. pylori have been reported in studies including patients
from low socio-economic environments [3,4]. Large genomic
variations were seen between patients in the present study, as
well as in others [2–5]. This can be explained by the natural
competence of H. pylori allowing easy uptake of extracellular
DNA, or by the high rate of genomic recombination events
that occur with this organism [2,14].
The cagA gene encodes for the protein CagA. Some studies
have shown that duodenal ulceration, gastric atrophy and gastric
carcinoma are more common in patients infected with cagA+
than cagA strains [15,16]. Other studies have found it difficult
to relate peptic ulceration and carcinoma with the presence of
cagA [16,17]. In one of these studies, 70% of isolates from
individuals with asymptomatic gastritis were cagA+, and these
authors conclude that cagA is not a useful marker to distinguish
virulence in H. pylori strains [16]. Our results, with three cagA+
patients, one cagA patient, and one patient with both cagA+
and cagA strains before and after treatment, indicate that the
presence of the cagA gene is not related to recrudescence of H.
pylori.
The vacA gene is always present, even if the toxin is not
always expressed. The gene varies in two main regions, the
signal sequence (s1/s2) and the mid-region (m1/m2a/m2b).
The s1 variant seems to be more often associated with disease
than s2 strains [18]. Our most common pattern was s1 m2,
except in one patient, who also harbored s2 m1 strains, which
is in accordance with previous studies [19].
In conclusion, each of our patients seemed to be colonized
with a single strain of H. pylori, and treatment failures in four
of 30 patients were apparently caused by recrudescence. AP-
PCR seems to discriminate equally well between different
strains compared to RFLP, and could therefore be recom-
mended for typing a large number of strains. The presence of
cagA or the different alleles of vacA did not seem to be indicators
of treatment failure.
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